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SUMMARY 
Myxoedema coma is a rare life-threatening disease, and it is essential that it is managed appropriately to reduce the 
associated high mortality. However, in the setting where efficient healthcare delivery is hampered by inadequacies, 
the management of such cases may pose a significant challenge. We present the case of a middle-aged woman diag-
nosed with myxoedema coma and severe hyponatremia. The case report highlights some of the challenges that may 
be encountered during the management of myxoedema coma in similar settings and outlines the management strate-
gies undertaken to overcome them in the absence of national guidelines. It also brings to the fore the need for clini-
cians to look out for clinical features suggestive of hypothyroidism particularly among high risk individuals for early 
diagnosis and treatment.  
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INTRODUCTION 
Myxoedema coma (MC) is an uncommon but severe, 
life-threatening form of decompensated hypothyroid-
ism.1 The incidence in western countries is reported to 
be 0.22 million per year, however, there is a paucity of 
data from countries adjacent to the equator.2 Myxoede-
ma coma is a medical emergency associated with high 
mortality rates ranging from 25–60% even with the best 
possible treatment and settings.1,3 Patients need to be 
treated in an intensive care unit with strict compliance 
to recommended management principles as much as 
possible.4  
 
However in healthcare facilities inundated by inadequa-
cies, some of these commonly recommended treatment 
modalities may either not be available or not easily ac-
cessible. These insufficiencies include the unavailability 
of the required facilities for the diagnosis, treatment and 
monitoring of critically-ill patients. This can make the 
proper management of patients with MC a formidable 
task. We present a report of a patient managed for MC 
with severe hyponatraemia to highlight some difficulties 
that may be encountered in the management of such 
patients in similar settings in Ghana. 
 
CASE REPORT 
A 53-year-old female, was admitted at a secondary care 
facility with a two-day history of vomiting and extreme 
weakness with inability to walk or sit. She was noted to 
have recurrent episodes of both alteration of conscious-
ness and hypotension with impalpable peripheral pulses. 
She was managed as a case of cardiogenic shock due to 
myocardial infarction or possible pulmonary embolism. 
Echocardiography performed outside the hospital re-
vealed mild pericardial effusion, prompting the suspi-
cion of hypothyroidism. A thyroid function test con-
firmed the diagnosis of primary hypothyroidism and she 
was subsequently referred to the endocrinology unit of a 
teaching hospital. She was brought in by her daughter 
who confirmed that the patient had been experiencing 
generalized weakness for the past 3years which became 
severe prior to presentation.  
 
In addition, she had complained of fatigue, lethargy, 
constipation, swelling of the feet, hair loss and had de-
veloped a slow speech with hoarseness of voice. There 
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She had hypertension and was on Amlodipine 10mg 
once daily. There was no past history of thyroidectomy, 
no previous exposure to radiation and no personal or 
family history of thyroid disease. 
 
On physical examination she had facial puffiness, non-
pitting oedema of hands and feet, dry coarse skin and 
alopecia. There was pallor of her mucous membranes, 
she was anicteric with a temperature of 36.7oC. She had 
a pulse rate of 48beats per minute, regular but of small 
volume with blood pressure of 70/50mmHg. Jugular 
venous pressure was not raised, her apex was not visible 
or palpable. The first and second heart sounds were 
heard but soft in nature.  Her respiratory effort was poor 
with oxygen saturation of 81% on room air, arterial 
blood gases however could not be done. The Glasgow 
coma scale (GCS) was 4/15. She had hypotonia and 
power of zero in all her limbs.   
 
Biochemical results from the referring hospital showed 
a TSH of 90.6uIU/L (0.34-5.6), sodium of 92mmol/L 
(135-150) and potassium of 2.3mmol/L (3.5-5.0) (Table 
1). A diagnosis of MC with severe hyponatraemia and 
hypokalaemia in a patient with primary hypothyroidism 
was made and the possibility of a pericardial tamponade 
was investigated. Laboratory and radiological investiga-
tions were also performed to identify the possible pre-
cipitating condition which in this instance was myocar-
dial infarction, stroke or infection.  
 
A repeat TSH, sodium and potassium on presentation 
were 138uIU/L, 98mmol/L and 3.4mmol/L respectively 
(Table 1). Troponin I and T were 0.16ng/ml (0.00-0.16) 
and 0.017ng/ml (0.000-0.014) respectively. Electrocar-
diography done showed sinus bradycardia with small 
voltages and chest X-ray revealed cardiomegaly. A se-
cond echocardiography showed hypertensive heart dis-
ease and mild pericardial effusion with no evidence of 
pericardial tamponade.  
 
Computed Tomographic Scan of brain was normal. 
Urine culture yielded E coli sp. Other results included 
random serum cortisol of 1029nmol/L [171 – 536], 
haemoglobin 6.5g/dl with normocytic, normochromic 
cells, white blood cells count of 11.9 x 109/L with neu-
trophilia. Serum total and LDL cholesterol of 
4.24mmol/l and 3.29mmol/L respectively were record-
ed.  Ultrasonography of the thyroid gland revealed a 
heterogeneous gland, which was otherwise normal. Thy-
roid antibodies namely thyroglobulin and thyroid perox-
idase antibodies were not elevated.  
 
The patient had to be managed on the medical ward 
since no bed was available in the intensive care unit of 
the hospital. Oxygen was given by face mask and her 
oxygen saturation later increased to 99%. Due to the 
possibility of an underlying myocardial infarction (ECG 
had not been done yet) and the lack of cardiac monitor-
ing, she was cautiously started on Levothyroxine 
100micrograms via nasogastric (NG) tube.  
 
Oral Levothyroxine was given instead of the recom-
mended IV Levothyroxine (T4) or Tri-iodothyronine 
(T3) because these parenteral preparations were not 
available in Ghana at the time. The dose of levothyrox-
ine was subsequently increased to 125micrograms after 
ECG, troponins and echocardiography results made the 
diagnosis of myocardial infarction unlikely. The hypo-
natremia was corrected by giving IV hypertonic saline 
in addition to fluid restriction and the avoidance of hy-
potonic IV fluids. The sodium requirement was estimat-
ed based on the formula:  
 
Sodium requirement = total body water x (desired sodi-
um concentration - current sodium concentration). We 
aimed at increasing sodium levels by a maximum of 
8mmol/L within 24hours. The estimated sodium re-
quirement of 240mmol in 24hours was administered by 
adding approximately 22mls of 23% hypertonic saline 
to a litre of 0.9% saline. A repeat sodium level was only 
possible on the third day of admission in our circum-
stances (Table 1). The hypertonic saline was given as 
and when available until her serum sodium was 
129mmol/L in the second week of admission.  
 
Hypokalaemia was initially corrected by giving IV po-
tassium chloride 20mmol in 500ml of normal saline and 
subsequently maintained on oral potassium chloride 
1200mg three times daily.  Intravenous hydrocortisone 
100mg 8hourly was started after random serum cortisol 
sample was taken. This was however stopped upon the 
receipt of the cortisol result which was suggestive of an 
appropriate adrenocortical response to stress. She de-
veloped recurrent episodes of hypoglycaemia and had to 
be fed frequent small meals to correct and prevent these 
episodes. The urinary tract infection was treated with IV 
Ceftriaxone 2g once daily. 
 
By the second day the patient was conscious but 
drowsy, blood pressure and pulse rate had increased 
averaging about 100/60mmHg and 80 beats per minute 
respectively. She was fully conscious and alert on the 
third day with an increase in power in all the limbs to 
grade 3 by the ninth day. Her temperature initially in-
creased from 36.7oC to 38.1oC by the fourth day but 
later subsided with the antibiotic therapy.  
 
On the tenth day of admission her antihypertensive 
medication had to be introduced and she was subse-
quently discharged home on oral levothyroxine 
125micrograms once daily. After a month of thyroxine 
therapy, the facial and bodily swelling had completely 
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92 2.3 61 90.6 <5.1 
Presentation 98 3.4 58 138 <5.1 
Day 3 111 3.4 73 - - 
2months 134 4.5 - 0.9 - 
4months 137 4.0 105 1.07 - 
Normal 
range 





Myxoedema coma (MC) is a rare, life threatening medi-
cal emergency.1 About 95% of all cases of MC coma is 
due to primary hypothyroidism (primary disorder of 
thyroid gland) with central hypothyroidism (disorder of 
the pituitary or hypothalamus) constituting about 5%.1 
Myxoedema coma is more common in elderly females 
often with longstanding, undiagnosed hypothyroidism 
with infection being the leading precipitating factor3,5 as 
demonstrated by our patient.  
 
Cerebrovascular accidents, congestive cardiac failure, 
gastrointestinal bleeding, and various sedative drugs 
may also precipitate MC.6 Another common precipitat-
ing factor is the discontinuation of thyroxine replace-
ment in critically ill patients.4 However for some pa-
tients, hypothyroidism is first diagnosed at the time of 
MC as shown in this report.7 
 
Diagnostic challenges 
Our patient had clinical features suggestive of hypothy-
roidism long before her presentation. However, delay in 
seeking medical attention could have contributed to the 
late diagnosis of hypothyroidism. In addition, clinical 
features of hypothyroidism may be non-specific and 
without a high index of suspicion diagnosis is often de-
layed.4 This case highlights the importance of screening 
for hypothyroidism in patients with suggestive clinical 




Myxoedema coma is a medical emergency and the fol-
lowing principles are essential in its management: (a) 
intensive care treatment for continuous monitoring of 
the cardiorespiratory status and for ventilatory support 
(b) appropriate fluid management and correction of hy-
potension and abnormal electrolyte levels, (c) aggres-
sive management of precipitating factors and steroid 
supplementation if required, (d) thyroid hormone re-
placement.4 
 
Our first challenge was managing our patient with MC 
with poor prognostic factors such as hypotension, brad-
ycardia, sepsis and a low GCS 9,10 on the medical ward 
without adequate cardiopulmonary monitoring and sup-
port due to the limited capacity of our ICU at the time. 
In Ghana it is not uncommon to find secondary and ter-
tiary healthcare facilities where ICUs are either not 
available or not readily accessible. 
 
Her altered sensorium was as a result of both the myx-
oedema coma and severe hyponatraemia; an indication 
for primary treatment of hyponatremia. 11 The patho-
physiology of hyponatraemia in the setting of MC is 
multifactorial.12,13,14 It is well established that the overly 
rapid correction of hyponatremia increases the risk of 
developing Osmotic Demyelination Syndrome 
(ODS).11,15 Serum sodium concentration <105 mmol/L 
and hypokalaemia, both of which our patient had, are 
some of the factors associated with a high risk of ODS.6  
 
Therefore adhering to recommended rate of correction 
of sodium of 4-8 mmol/L in first 24 hours and 12-
14mmol/L within 48hours was extremely critical.17 The 
use of hypertonic saline in the management of our pa-
tient was life-saving, however the difficulty was the 
availability of hypertonic saline making its administra-
tion erratic. Secondly, the recommended 4 to 6hourly 
monitoring of electrolytes to ensure the appropriate cor-
rection rate of hyponatraemia 11 was a challenge due to 
the high cost of biochemical tests.  
 
Indeed all the endocrine-related laboratory investiga-
tions and most of the other biochemical tests were per-
formed outside the hospital at a greater cost to our pa-
tient because the hospital’s laboratory was not running 
these tests at the time. Furthermore, the timely receipt of 
results for meaningful interpretation and appropriate 
intervention was sometimes a major obstacle. We were 
only able to repeat sodium level after 48hours of thera-
py and fortunately the rate of rise of 13mmol/L seen in 
our patient did not exceed the recommended rate.  
 
Thyroid hormone replacement 
Thyroid hormone therapy remains the backbone of 
treatment of patients with MC. The major considera-
tions of thyroid hormone therapy are the dose and route 
of administration, which have a bearing on the absorp-
tion, distribution, onset of action, efficacy and safety of 
the administered hormone preparation.4  
The initial recommended treatment is IV T4 100–500µg 
as a bolus to saturate the body pool followed by T4 at a 
dose of 50–100µg daily IV or orally.1 The T4 concentra-
tions rise acutely to levels above normal and slowly gets 
converted to T3 the active hormone.18 However in the 
setting of severe illness, there may be a decreased con-
version of T4 to T3 favouring the use of T3 by some in 
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On the other hand, it should be noted that thyroid hor-
mone administration is associated with the risk of pre-
cipitating angina, heart failure or an arrhythmia and 
treatment should be started slowly especially among 
those with underlying cardiovascular disease.1,20 Our 
choice of therapy was limited to only oral T4 due to the 
lack of both IV preparations. Although oral T4 via NG 
tube has proved to be equally effective, a major draw-
back has been the poor absorption of orally adminis-
tered drugs in MC.4  
 
Against the backdrop of a possible myocardial infarc-
tion and in the absence of cardiac monitoring coupled 
with delays in confirming the diagnosis of myocardial 
infarction in this case, a relatively lower dose of oral T4 
was cautiously given via NG tube. Despite the challeng-
es encountered in her management coupled with the 
presence of significant predictors of mortality at presen-
tation, our patient made a remarkable recovery.  
 
CONCLUSION 
Myxoedema coma is a rare medical emergency which is 
associated with a high mortality rate. To improve the 
outcome of patients with myxoedema coma in similar 
settings and in the absence of local guidelines, early 
diagnosis and the adoption of the management strategies 
employed in this case are recommended. Furthermore, 
there is the need for the formulation of local guidelines 
for the management of myxoedema coma. Ultimately to 
overcome these management challenges, the collabora-
tive efforts of health institutions, policy makers and 
governmental bodies are needed to ensure the availabil-
ity and accessibility of the necessary resources to guar-
antee optimum care in Myxoedema coma. 
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